New Drug Pairing for Pancreatic Cancer Shows Promise in Lab Models

According to research, a combination of drugs was dramatically more effective and less prone to resistance than treatment with a KRAS inhibitor alone for pancreatic cancer.

Related Keywords

United States ,San Diego ,California ,University Of California San Diego ,American ,Andrew Lowy ,Herve Tiriac ,Gulay Kcmontecillo ,Cancer Research ,Cancer Surgery At Moores Center ,Department Of Surgery ,Division Of Surgical Oncology ,Uc San Diego Health ,American Association For Cancer Research ,Moores Cancer Center ,Technology Network ,Uc San Diego School Of Medicine ,California San Diego School ,American Association ,Diego School ,Mirati Therapeutics ,Surgical Oncology ,Cancer Surgery ,Moores Cancer ,